ESMO TAT 2023 | Selecting patients with prostate cancer to be treated with IO

Pasquale Rescigno, MD, PhD, Newcastle University, Newcastle, UK, comments on enhancing immunotherapies (IO) in prostate cancer. Further research in the field of liquid biomarkers and biopsy sequencing will enable identification of patients with prostate cancer who will benefit from immunotherapies. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.